Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 24, 2012

View Archived Issues

Novel biomarker presented by the National Institute on Drug Abuse

CSL-362 shows efficacy in AML animal models

German researchers patent novel anti-PRL-R antibody

Novel protein kinase B inhibitors presented by German researchers

Merck KGaA discloses new TBK1 and IKK-epsilon inhibitors

Bayer Intellectual Property presents novel CDK inhibitors

Janssen Pharmaceutica prepares novel glucagon receptor antagonists

The University of Dundee synthesizes new D4/5-HT1A receptor ligands

Researchers develop a novel hTSLP+/- xenograft model to study B-ALL

Investigators report results of clinical study testing Wilms tumor protein analogue peptide vaccine

TLS obtains IND clearance for clinical trial protocol based on crowdsourcing

Abexinostat monotherapy shows significant clinical activity in phase II trials

Novo Nordisk provides update on three clinical development programs

Actelion's novel antibiotic advances into phase III development

Novel mRNA-based influenza vaccine presented by CureVac

Genentech unveils an indicator of LRRK2 kinase activity and novel LRRK2 inhibitor

NPS gains FDA approval for Gattex in treatment of adult short bowel syndrome

New administration route approved for bortezomib in Japan

Exjade approved in Europe for iron overload in patients with thalassemia

Celgene presents promising in vitro results for CC-122

FDA approves Varizig for reducing the severity of chickenpox in individuals at high risk

FDA approves Alexza's Adasuve for acute treatment of agitation

Application filed for use of OneDuro Patch as once-daily treatment of chronic pain in Japan

EMA accepts MAA for aripiprazole depot formulation

FDA expands approval of Tamiflu

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...